Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?
{{output}}
To date, no overall survival benefit has been proven from the immediate treatment of patients with asymptomatic follicular lymphoma (FL) compared with expectant management. Watchful waiting therefore became the standard of care, with patients closely monitored... ...